LGLiang Guo

Liang Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liang Guo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Zhao

    Shandong public health clinical center

    2 shared publications
  • Bo Tao

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

    2 shared publications
  • Bo Tao

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China

    1 shared publication
  • Chao Ma

    Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, Henan, China

    1 shared publication
  • Dacheng Xie

    Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, China

    1 shared publication
  • Enkuo Zheng

    Second Hospital of Ningbo

    1 shared publication

Latest Publications

  • Open Access

    Differential Diagnosis of Pulmonary Arterial Hypertension via Deep Multimodal Modeling of Noninvasive Measurements

    by Siqiang Zheng, Enkuo Zheng, Liang Guo, Lei Xie, Bin Zhao, Qi Hong, Xuefei Hu, Bo Tao

    Background Pulmonary hypertension (PH) is a rare yet progressive disorder characterized by elevated blood pressure in the arteries of the lungs, often presenting without an evident cause. The distinction between pulmonary arterial hypertension (PAH) and PH due to left heart disease (PH-LHD) is crucial due to differences in treatment approach and prognosis. A correct diagnosis is essential to ensuring that patients receive the appropriate treatment. However, the current diagnosis of PAH and PH-LHD faces clinical limitations due to its reliance on invasive hemodynamic measurements or the limits of data modeling. Methods We conducted a retrospective study involving 905 PH patients from Shanghai Pulmonary Hospital, incorporating CT images and clinical textual data. A heterogeneous graph neural network was constructed on multimodal data. We developed and validated a heterogeneous network to predict the probability of PAH and PH-LHD. The new method exhibits strong discrimination between PAH and PH-LHD. Findings In the multiple cross-validations, it achieved a 0.943 AUC when using a combination of image and textual data, a 0.869 AUC for only textual variables, and a 0.715 AUC for only images. It also evaluated the type-dependent performances, yielding the best AUC (0.896) when using a subgroup of variables. The best performance (AUC=0.809) can be achieved by using only ECG variables in our model. Interpretation Our study provides a quantitative rationale for modulating multimodal data to enhance differential diagnosis of PAH and PH-LHD with only noninvasive measurements.

  • Open Access

    Exploring the prognostic analysis of autophagy and tumor microenvironment based on monocyte cells in lung cancer

    by Bo Tao, Ziming Wang, Dacheng Xie, Hongxue Cui, Bin Zhao, Juanjuan Li, Liang Guo

    A deep understanding of the biological mechanisms of lung cancer offers more precise treatment options for patients. In our study, we integrated data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) to investigate lung adenocarcinoma. Analyzing 538 lung cancer samples and 31 normal samples, we focused on 3076 autophagy-related genes. Using Seurat, dplyr, tidyverse, and ggplot2, we conducted single-cell data analysis, assessing the quality and performing Principal Component Analysis (PCA) and t-SNE analyses. Differential analysis of TCGA data using the “Limma” package, followed by immune infiltration analysis using the CIBERSORT algorithm, led us to identify seven key genes. These genes underwent further scrutiny through consensus clustering and gene set variation analysis (GSVA). We developed a prognostic model using Lasso Cox regression and multivariable Cox analysis, which was then validated with a nomogram, predicting survival rates for lung adenocarcinoma. The model’s accuracy and universality were corroborated by ROC curves. Additionally, we explored the relationship between immune checkpoint genes and immune cell infiltration and identified two key genes, HLA-DQB1 and OLR1. This highlighted their potential as therapeutic targets. Our comprehensive approach sheds light on the molecular landscape of lung adenocarcinoma and offers insights into potential treatment strategies, emphasizing the importance of integrating single-cell and genomic data in cancer research.


  • Retracted
    Open Access

    Cyclin D3 predicts disease-free survival in breast cancer

    by Yayun Chi, Sheng Huang, Mengying Liu, Liang Guo, Xuxia Shen, Jiong Wu

    Cyclin D3, which induces progression through the G1 phase of the cell cycle, is a regulator of Cyclin-dependent kinases 4 and 6. Previous studies revealed that abnormal expression of Cyclin D3 was found in many different cancers. However, the role of Cyclin D3 in breast cancer (BC) remains unknown. The aim of this study is to examine the expression pattern of Cyclin D3 in BC and to evaluate its biological role and clinical significance in prognosis prediction. The mechanism involved is also evaluated. Immunohistochemical staining was used to detect the expression of Cyclin D3. qRT-PCR was used to detect the mRNA level of Cyclin D3 in BC tissues and BC cell lines. Transwell assay was used to examine the role of Cyclin D3 in the migration and invasion of BC cells. Mass Spectrometry was used to search for the interacting protein with Cyclin D3. Co-Immunoprecipitation assay and GST-Pull Down assay were used to validate the interaction of Cyclin D3 and its interaction protein. Through detecting Cyclin D3 expression in 243 breast cancer patients’ tissue array, we found Cyclin D3 expression was correlated with ER status (p = 0.000), PR status (p = 0.001), HER2 status (p = 0.002) and tumor differentiation (p = 0.045). The Kaplan–Meier survival curves indicated that the disease free survival (DFS) was significantly poor in high Cyclin D3 expression BC patients (p = 0.004). Furthermore, expression of Cyclin D3 was significantly associated with BC prognosis and was shown to be an independent prognostic marker in breast cancer (p = 0.028). By IHC staining and qPCR detection, Cyclin D3 expression was found to be down-regulated both in BC tissues and in BC cell lines compared with the corresponding normal controls. Further investigation showed Cyclin D3 was involved in the metastasis of BC cells and physically interacted with actin in vivo and in vitro. Our studies revealed that Cyclin D3 was upregulated in breast cancer and represented a novel predictor of BC prognosis.